Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Cancer Discov. 2015 Nov 10;6(1):96–107. doi: 10.1158/2159-8290.CD-15-1056

Figure 4.

Figure 4

PF-06463922 inhibits viability of neuroblastoma cell-lines at concentrations corresponding to clinically relevant doses (≤ 100 nM). Dose-response curves for the effects of crizotinib (dashed blue curves) and PF-06463922 (red curves) on cell viability are shown for a series of neuroblastoma cell-lines driven by R1275Q-mutated ALK (A, B); F1174L-mutated ALK (C–F), F1245C-mutated ALK (G), and amplified wild-type ALK (H). NCI-H3122 cells, driven by an ALK translocation are shown for comparison (I), as well as two cell-lines that are not ALK dependent (J, K). Data points are plotted as means ± SD for at least three different experiments, with blue triangles for crizotinib and red squares for PF-06463922. The IC50 curves for individual experiments are also plotted, with mean IC50 values obtained over the three experiments listed in Table S1..